Drug intelligence / Profile preview

AH001

Development stage: Preclinical
Lead developer: AnHorn Medicines
Administration: Topical

Overview

AH001 is a precision cancer therapy being developed by Apricity Health for the treatment of patients who do not respond to the existing standard of care. It is the lead candidate in the company's pipeline and is developed using a human-insight-based approach that leverages real-world data to identify targets driving resistance to current therapies. The program utilizes blood-based biomarkers for patient selection and is designed for precision clinical development. As of early 2024, AH001 is in the preclinical/pre-IND stage of development.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on AH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AH001.

Explore the full profile